<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="tca70016" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Thorac Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Thorac Cancer</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1759-7714</journal-id><journal-id journal-id-type="publisher-id">TCA</journal-id><journal-title-group><journal-title>Thoracic Cancer</journal-title></journal-title-group><issn pub-type="ppub">1759-7706</issn><issn pub-type="epub">1759-7714</issn><publisher><publisher-name>John Wiley &#x00026; Sons Australia, Ltd</publisher-name><publisher-loc>Melbourne</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40001320</article-id><article-id pub-id-type="pmc">PMC11860276</article-id><article-id pub-id-type="doi">10.1111/1759-7714.70016</article-id><article-id pub-id-type="publisher-id">TCA70016</article-id><article-id pub-id-type="other">TCA-OA-11-2024-11928.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A Comprehensive Analysis of <italic toggle="no">FGF</italic>/<italic toggle="no">FGFR</italic> Signaling Alteration in <styled-content style="fixed-case" toggle="no">NSCLC</styled-content>: Implications in Prognosis and Microenvironment</article-title></title-group><contrib-group><contrib id="tca70016-cr-0001" contrib-type="author"><name><surname>Huang</surname><given-names>Ziling</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0899-1270</contrib-id><xref rid="tca70016-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="tca70016-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="tca70016-cr-0002" contrib-type="author"><name><surname>Li</surname><given-names>Leyao</given-names></name><xref rid="tca70016-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="tca70016-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="tca70016-cr-0003" contrib-type="author"><name><surname>Cai</surname><given-names>Xu</given-names></name><xref rid="tca70016-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="tca70016-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="tca70016-cr-0004" contrib-type="author"><name><surname>Wang</surname><given-names>Shen</given-names></name><xref rid="tca70016-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="tca70016-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="tca70016-cr-0005" contrib-type="author"><name><surname>Jia</surname><given-names>Yun</given-names></name><xref rid="tca70016-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="tca70016-cr-0006" contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Yuan</given-names></name><xref rid="tca70016-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="tca70016-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>lumoxuan2009@163.com</email></address></contrib></contrib-group><aff id="tca70016-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Fudan University Shanghai Cancer Center</institution>
<city>Shanghai</city>
<country country="CN">China</country>
</aff><aff id="tca70016-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Oncology</named-content>
<institution>Shanghai Medical College of Fudan University</institution>
<city>Shanghai</city>
<country country="CN">China</country>
</aff><aff id="tca70016-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">School of Computer Science</named-content>
<institution>Fudan University</institution>
<city>Shanghai</city>
<country country="CN">China</country>
</aff><aff id="tca70016-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Butiange Co. Ltd</institution>
<city>Shanghai</city>
<country country="CN">China</country>
</aff><aff id="tca70016-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Alpha X Biotech (Beijing) Co.</institution>
<city>Beijing</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Yuan Li (<email>lumoxuan2009@163.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>16</volume><issue seq="130">4</issue><issue-id pub-id-type="doi">10.1111/tca.v16.4</issue-id><elocation-id>e70016</elocation-id><history>
<date date-type="rev-recd"><day>30</day><month>1</month><year>2025</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>07</day><month>2</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Australia, Ltd--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Thoracic Cancer</italic> published by John Wiley &#x00026; Sons Australia, Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:TCA-16-e70016.pdf"/><abstract><title>ABSTRACT</title><p>Fibroblast Growth Factor (FGF) ligands and their receptor have been identified as the potent target in non&#x02013;small cell lung cancer (NSCLC). However, the clinicopathological and microenvironmental characteristics of <italic toggle="no">FGF/FGFR</italic> in NSCLC remain poorly elucidated. Here, we summarize 4656 NSCLCs and analyze clinicopathological features in 478 <italic toggle="no">FGF/FGFR</italic> altered cases. AI analysis and multiplex immunofluorescence staining are used to reveal microenvironment features. First, around 10.27% NSCLC carry <italic toggle="no">FGF/FGFR</italic> variant. Squamous cell carcinoma (41.95%) is much more than adenocarcinoma (8.32%). In 118 pathogenic variant (PV) cases, the most frequent variant is <italic toggle="no">FGF/FGFR</italic> copy number increase (83.05%), the second is <italic toggle="no">FGFR</italic> gene fusion (11.86%). Surprisingly, <italic toggle="no">CCND1</italic> always co&#x02010;amplifies with <italic toggle="no">FGF19</italic> (100.00%). Furthermore, <italic toggle="no">FGF</italic> PV is an independent risk factor for poor outcomes (overall survival: HR&#x02009;=&#x02009;3.781, disease&#x02010;free survival: HR&#x02009;=&#x02009;3.340). And one&#x02010;third of <italic toggle="no">FGFR3&#x02010;TACC3</italic> fusion cases show clear cytoplasm in histology. Either <italic toggle="no">CCND1/FGF19</italic> co&#x02010;amplification or <italic toggle="no">KRAS</italic> co&#x02010;mutation is closely related to cigarette exposure, and <italic toggle="no">KRAS</italic> co&#x02010;mutation acts as an independent factor of poor prognosis. Finally, the <italic toggle="no">FGF/FGFR1/NOTCH1</italic> within <italic toggle="no">RB1</italic> variant group has a remarkably high ratio of inner&#x02010;tumor CD8+ T cell infiltration, non&#x02010;exhausted T cells, exhausted T<sup>CD8+PD&#x02010;1+LAG3&#x02212;</sup> cells, and T<sub>RM</sub>
<sup>CD8+CD69+CD103+</sup>cells. Overall, this study provides a comprehensive analysis of <italic toggle="no">FGF/FGFR</italic> alteration in NSCLC. The <italic toggle="no">FGF/FGFR</italic> alteration mainly arises&#x000a0;in squamous cell carcinoma. Both <italic toggle="no">FGF</italic> PV and <italic toggle="no">KRAS</italic> are the independent factors for poor prognosis. To our knowledge, this is the first report to describe an inflamed microenvironment recruited by <italic toggle="no">NOTCH1</italic>/<italic toggle="no">RB1</italic> co&#x02010;mutation, indicating potential benefit from immunotherapy.</p></abstract><abstract abstract-type="graphical"><p>This study summarizes 4656 lung cancer cases examined by next&#x02010;generation sequencing (NGS) and demonstrates that both <italic toggle="no">FGF</italic> PV and <italic toggle="no">KRAS</italic> are the independent factors for poor prognosis. This is the first report to describe an inflamed microenvironment recruited by <italic toggle="no">NOTCH1</italic>/<italic toggle="no">RB1</italic> co&#x02010;mutation subtype, which implies the potential benefit from immunotherapy. All these findings provide a comprehensive analysis about <italic toggle="no">FGF/FGFR</italic> alteration in large&#x02010;scale Asian cohort.<boxed-text position="anchor" content-type="graphic" id="tca70016-blkfxd-0001"><graphic xlink:href="TCA-16-e70016-g003.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="tca70016-kwd-0001">
<italic toggle="no">FGF/FGFR</italic> signaling</kwd><kwd id="tca70016-kwd-0002">microenvironment</kwd><kwd id="tca70016-kwd-0003">NSCLC</kwd><kwd id="tca70016-kwd-0004">prognosis</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Beijing Xisike Clinical Oncology Research Foundation
</institution><institution-id institution-id-type="doi">10.13039/100018904</institution-id></institution-wrap></funding-source><award-id>Y&#x02010;Young2024&#x02010;0371</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Key Research and Development Program of China Stem Cell and Translational Research
</institution><institution-id institution-id-type="doi">10.13039/501100013290</institution-id></institution-wrap></funding-source><award-id>2021YFF1201001</award-id></award-group><award-group id="funding-0003"><funding-source>Institution and Governmental Cooperative Project, Shanghai Xuhui District Science and Technology Committee</funding-source><award-id>23XHYD&#x02010;12</award-id></award-group></funding-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="12"/><word-count count="7100"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:26.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="tca70016-ntgp-0001"><fn fn-type="funding" id="tca70016-note-0001"><p>
<bold>Funding:</bold> This study was supported by Beijing Xisike Clinical Oncology Research Foundation, (No. Y&#x02010;Young2024&#x02010;0371); National Key Research and Development Program of China Stem Cell and Translational Research, (No.2021YFF1201001); Institution and Governmental Cooperative Project, Shanghai Xuhui District Science and Technology Committee, (No.23XHYD&#x02010;12).</p></fn><fn fn-type="equal" id="tca70016-note-0002"><p>Ziling Huang, Leyao Li, Xu Cai co&#x02010;first author: Contributed equally to this article.</p></fn></fn-group></notes></front><body id="tca70016-body-0001"><sec id="tca70016-sec-0001"><label>1</label><title>Introduction</title><p>Lung cancer is a major threatening issue for high mortality in worldwide [<xref rid="tca70016-bib-0001" ref-type="bibr">1</xref>, <xref rid="tca70016-bib-0002" ref-type="bibr">2</xref>, <xref rid="tca70016-bib-0003" ref-type="bibr">3</xref>]. Non&#x02013;small cell lung cancer (NSCLC) is one of the common histological types in lung cancer, accounting for around 85% of the total cases&#x000a0;[<xref rid="tca70016-bib-0004" ref-type="bibr">4</xref>, <xref rid="tca70016-bib-0005" ref-type="bibr">5</xref>, <xref rid="tca70016-bib-0006" ref-type="bibr">6</xref>]. The identification of the driver genes of NSCLC has therefore emerged as a prominent area of research. Except for the famous key drivers, like <italic toggle="yes">EGFR</italic>, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">HER2</italic>, <italic toggle="yes">BRAF</italic>, <italic toggle="yes">ALK</italic>, <italic toggle="yes">RET</italic>, <italic toggle="yes">ROS1</italic>, and <italic toggle="yes">c&#x02010;MET</italic>, some potential targets reveal a new page in NSCLC anticancer therapy [<xref rid="tca70016-bib-0005" ref-type="bibr">5</xref>, <xref rid="tca70016-bib-0007" ref-type="bibr">7</xref>, <xref rid="tca70016-bib-0008" ref-type="bibr">8</xref>, <xref rid="tca70016-bib-0009" ref-type="bibr">9</xref>, <xref rid="tca70016-bib-0010" ref-type="bibr">10</xref>]. Revealing novel oncogenic driver variants is gradually becoming urgent in NSCLC.</p><p>Recently, fibroblast growth factor (FGF) ligands [<xref rid="tca70016-bib-0011" ref-type="bibr">11</xref>, <xref rid="tca70016-bib-0012" ref-type="bibr">12</xref>, <xref rid="tca70016-bib-0013" ref-type="bibr">13</xref>, <xref rid="tca70016-bib-0014" ref-type="bibr">14</xref>, <xref rid="tca70016-bib-0015" ref-type="bibr">15</xref>] and their receptors [<xref rid="tca70016-bib-0013" ref-type="bibr">13</xref>, <xref rid="tca70016-bib-0014" ref-type="bibr">14</xref>, <xref rid="tca70016-bib-0015" ref-type="bibr">15</xref>, <xref rid="tca70016-bib-0016" ref-type="bibr">16</xref>, <xref rid="tca70016-bib-0017" ref-type="bibr">17</xref>, <xref rid="tca70016-bib-0018" ref-type="bibr">18</xref>] alteration have been identified as the potential and sensitive therapeutic targets for NSCLC. <italic toggle="yes">FGFR</italic> events, including amplification, fusion, and mutation, are the most prevalent type of <italic toggle="yes">FGF/FGFR</italic> alteration observed in lung cancer&#x000a0;[<xref rid="tca70016-bib-0014" ref-type="bibr">14</xref>, <xref rid="tca70016-bib-0017" ref-type="bibr">17</xref>]. There is a growing number of literatures that have reported patients who achieved disease response on FGFR inhibitor treatment [<xref rid="tca70016-bib-0019" ref-type="bibr">19</xref>, <xref rid="tca70016-bib-0020" ref-type="bibr">20</xref>, <xref rid="tca70016-bib-0021" ref-type="bibr">21</xref>, <xref rid="tca70016-bib-0022" ref-type="bibr">22</xref>, <xref rid="tca70016-bib-0023" ref-type="bibr">23</xref>, <xref rid="tca70016-bib-0024" ref-type="bibr">24</xref>, <xref rid="tca70016-bib-0025" ref-type="bibr">25</xref>], including the FDA&#x02010;approved pemigatinib, erdafitinib, infigratinib (BGJ398), and futibatinib (TAS&#x02010;120) specifically [<xref rid="tca70016-bib-0018" ref-type="bibr">18</xref>, <xref rid="tca70016-bib-0026" ref-type="bibr">26</xref>, <xref rid="tca70016-bib-0027" ref-type="bibr">27</xref>, <xref rid="tca70016-bib-0028" ref-type="bibr">28</xref>]. However, there is a scarcity of studies on the survival outcomes and clinicopathological characteristics associated within the complex diversity of mutations in <italic toggle="yes">FGF/FGFR</italic> signaling pathway, and the roles of co&#x02010;mutations in modulating &#x000a0;the tumor microenvironment remain poorly understood.</p><p>Here, a total of 4656 NSCLC cases examined by next&#x02010;generation sequencing (NGS) are included in this study. We summarize 478 cases harboring <italic toggle="yes">FGF/FGFR</italic> alteration, and then analyze the relationship with clinicopathologic characteristics and prognosis. To our knowledge, this report is the first to characterize&#x000a0;the tumor microenvironment associated with&#x000a0;<italic toggle="yes">FGF/FGFR</italic> alterations, and offers comprehensive insights into the landscape of <italic toggle="yes">FGF/FGFR</italic> alterations in NSCLC.</p></sec><sec sec-type="materials-and-methods" id="tca70016-sec-0002"><label>2</label><title>Materials and Methods</title><sec id="tca70016-sec-0003"><label>2.1</label><title>Patients and Samples</title><p>A total of 4656 NSCLC tissue samples were examined by next&#x02010;generation sequencing (NGS), including 236 squamous cell carcinoma cases and 3978 adenocarcinoma cases. Among them, 478 harbor <italic toggle="yes">FGF/FGFR</italic> alteration, which consist of 367 surgically resected specimens and 111 biopsy specimens. The surgical samples were collected between April 1, 2020 and July 31, 2023 from Fudan University Shanghai Cancer Center, China. The clinical data and molecular results were obtained from the patients' electronic medical records. Patients who had a prior history of other malignancy or neoadjuvant chemotherapy were excluded. Clinicopathological parameters including age, gender, smoking history, histology, pathological stage, pathological subtype, and features such as visceral pleural invasion (VPI) and lymphovascular invasion (LVI) were recorded. Never&#x02010;smoker was defined as having smoked fewer than 100 cigarettes during the individual's lifetime. Histological type was classified according to the 5th edition of the World Health Organization (WHO) classification. The pathologic stage was determined by the 8th Edition of the American Joint Committee on Cancer (AJCC) staging system [<xref rid="tca70016-bib-0029" ref-type="bibr">29</xref>]. The study was approved by the Institutional Review Board of Fudan University Shanghai Cancer Center.</p></sec><sec id="tca70016-sec-0004"><label>2.2</label><title>Multiplex Immunohistochemistry (mIHC) Staining</title><p>All the slides were deparaffinized in xylene for 10&#x02009;min and repeated three times and rehydrated in absolute ethyl alcohol for 5&#x02009;min and repeated twice, 95% ethyl alcohol for 5&#x02009;min, 75% ethyl alcohol for 2&#x02009;min, sequentially. Then the slides were washed with distilled water 3 times. A microwave&#x02010;oven was used for heat&#x02010;induced epitope retrieval; during epitope retrieval, the slides were immersed in boiling EDTA buffer (Alpha X Bio, Beijing, China) for 15&#x02009;min. Antibody Diluent/Block (Alpha X Bio, Beijing, China) was used for blocking. The mIHC staining part was performed and analyzed according to a 6&#x02010;plex&#x02010;7&#x02010;color panel, and specifications (with primary antibodies used) are as the follows: Panel 1: CD4(ET1609&#x02010;52, HUA&#x02010;BIO, CHINA), FOXP3 (ab20034, Abcam, Cambridge, UK), TGF&#x02010;&#x003b2;&#x000a0;(ab215715, Abcam, Cambridge, UK), FAP (ab207178, Abcam, Cambridge, UK), a&#x02010;SMA (ab124964, Abcam, Cambridge, UK) and PANCK (ZM0069, ZSGB&#x02010;BIO, CHINA). Panel 2: PD1(ZM0381, ZSGB&#x02010;BIO, CHINA), CD8 (ZA0508, ZSGB&#x02010;BIO, CHINA), CD69 (ab233396, Abcam, Cambridge, UK), CD103 (ET1611&#x02010;27, HUA&#x02010;BIO, CHINA), LAG3 (ab209236, Abcam, Cambridge, UK), and PANCK (ZM0069, ZSGB&#x02010;BIO, CHINA).</p><p>All the primary antibodies were incubated for 1&#x02009;h at 37&#x000b0;C. Then slides were incubated with Alpha X Ploymer HRP Ms.&#x02009;+&#x02009;Rb (Alpha X Bio, Beijing, China) for 10&#x02009;min at 37&#x000b0;C. Alpha X 7&#x02010;Color IHC Kit (Alpha X Bio, Beijing, China) was used for visualization. The correspondence between primary antibodies and fluorophores are listed: Panel 1: XTSA 480 (CD4), XTSA 520 (FOXP3), XTSA 570 (TGF&#x02010;&#x003b2;), XTSA 620 (FAP), XTSA 690 (a&#x02010;SMA) XTSA 780 (PANCK). Panel 2: XTSA 480 (CD8), XTSA 520 (PD1), XTSA 570 (CD69), XTSA 620 (CD103), XTSA 690 (LAG3) XTSA 780 (PANCK).</p><p>After each cycle of staining, heat&#x02010;induced epitope retrieval was performed to remove all the antibodies including primary antibodies and secondary antibodies. The slides were counter&#x02010;stained with DAPI for 5&#x02009;min and enclosed in Antifade Mounting Medium (I0052; NobleRyder, Beijing, China). Axioscan7 (ZEISS, Germany) was used for imaging the visual capturing.</p></sec><sec id="tca70016-sec-0005"><label>2.3</label><title>
<styled-content style="fixed-case" toggle="no">mIHC</styled-content> Image Analysis</title><p>Image analysis was performed with Halo (3.4, Indica Labs, United States). The random forest classifier was trained using manual annotation provided by the pathologist, including the classes &#x02018;stroma&#x02019;, &#x02018;tumor,&#x02019; and &#x02018;blank&#x02019;. Cell phenotyping was performed using the analysis algorithm, Highplex FL, where the nuclear detection sensitivity and the minimum intensity threshold for positive cell detection based on staining localization (nuclear, cytoplasmic or membrane) were defined. And CD8+ cell localization was also identified by measuring the infiltration distances of CD8+ cell from tumor boundary using the infiltration analysis module in Halo.</p></sec><sec id="tca70016-sec-0006"><label>2.4</label><title>
<styled-content style="fixed-case" toggle="no">HE</styled-content> Slides <styled-content style="fixed-case" toggle="no">AI</styled-content> Analysis</title><p>The tumor microenvironment feature tertiary lymphoid structure (TLS) was recognized and evaluated by an optimized YOLOv8 AI model. The germinal center formation is defined as the feature of mature TLS. The number of both immature and mature TLS are all calculated and exported. The final number included for analysis is the average of all HE slides of tumor area of one case.</p></sec><sec id="tca70016-sec-0007"><label>2.5</label><title>Molecular Analysis</title><p>Examination of <italic toggle="yes">FGF/FGFR</italic> signaling alteration by NGS used the Illumina NextSeq 500 platform with Oncoscreen Sequencing Panel (Burning Rock, Guangzhou, China), according to the standard protocol.</p></sec><sec id="tca70016-sec-0008"><label>2.6</label><title>Statistic</title><p>Statistical analyses were performed using the software package Statistical Package for Social Sciences, version 20.0, for Windows (SPSS). Chi&#x02010;square or Fisher's exact tests were used to identify the influence of clinicopathological parameters on different <italic toggle="yes">FGF/FGFR</italic> signaling variants. Pearson's correlation coefficient was calculated for the <italic toggle="yes">FGF/FGFR</italic> alterations and the paired mutations or PD&#x02010;L1 expression of NSCLC. Overall survival (OS) and disease&#x02010;free survival (DFS) were estimated using the Kaplan&#x02013;Meier method/Log&#x02010;rank (Mantel&#x02013;Cox) test, and prognostic factors were assessed using Cox proportional hazards survival regression analysis. OS: Length of time between the surgery date to the death date (including any cause) or the last follow&#x02010;up date. DFS: Length of time from the date of surgery to the timepoint of first recurrence/metastasis, death from any cause, or last follow&#x02010;up. All statistical values were determined using two&#x02010;tailed statistical analyses, and a <italic toggle="yes">p</italic> value &#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="tca70016-sec-0009"><label>3</label><title>Results</title><sec id="tca70016-sec-0010"><label>3.1</label><title>NGS Analyses Reveal Diversity in <italic toggle="yes">FGF/FGFR</italic> Alterations</title><p>First, in 4656 cases, 478 harbor <italic toggle="yes">FGF/FGFR</italic> alteration. The total variation rate is around 10.27% (478/4656) in NSCLC examined by NGS (Figure&#x000a0;<xref rid="tca70016-fig-0001" ref-type="fig">1A</xref>). Most <italic toggle="yes">FGF/FGFR</italic> variants are found in squamous cell carcinoma (Sq, 41.95%, 99/236, Figure&#x000a0;<xref rid="tca70016-fig-0001" ref-type="fig">1B</xref>) rather than adenocarcinoma (Ad, 8.32%, 331/3978, Figure&#x000a0;<xref rid="tca70016-fig-0001" ref-type="fig">1C</xref>). Furthermore, around 24.69% (118/478) cases harbor pathogenic variant (PV), 15 of them also harbor variant of only uncertain significance (VUS, 3.14%,15/478). The other 75.31% cases (360/478) carry VUS (Figure&#x000a0;<xref rid="tca70016-fig-0001" ref-type="fig">1D</xref>).</p><fig position="float" fig-type="FIGURE" id="tca70016-fig-0001"><label>FIGURE 1</label><caption><p>
<italic toggle="yes">FGF/FGFR</italic> signaling alteration shows diversity by NGS examination. (A) The <italic toggle="yes">FGF/FGFR</italic> variation rate is around 10.27% (478/4656) in NSCLC examined by next&#x02010;generation sequencing (NGS). (B) The percentage of <italic toggle="yes">FGF/FGFR</italic> alteration in squamous cell carcinoma (Sq) is 41.95% (99/236). (C) The percentage of <italic toggle="yes">FGF/FGFR</italic> alteration in adenocarcinoma (Ad) is 8.32% (331/3978). (D) In the total 478 <italic toggle="yes">FGF/FGFR</italic> alteration cases, 24.69% (118/478) cases harbor pathogenic variant (PV), fifteen of them also harbor variant of only uncertain significance (VUS, 3.14%,15/478). The other 75.31% cases (360/478) carry VUS. (E) In the 118 PV cases, <italic toggle="yes">FGF/FGFR</italic> copy number increase accounts for 83.05% (98/118, red+magenta+black), <italic toggle="yes">FGFR</italic> gene fusion ratio is 11.86% (14/118, yellow+magenta), more than half cases carry <italic toggle="yes">FGFR3&#x02010;TACC3</italic> gene fusion (57.14%, 8/14). And the percentage of <italic toggle="yes">FGFR</italic> gene missense mutation is around 7.63% (9/118, green+black). Inside these cases, two of them carry both <italic toggle="yes">FGFR</italic> gene fusion and copy number increase (magenta). One harbor both <italic toggle="yes">FGFR</italic> gene missense mutation and copy number increase (black). (F) In the 375 cases within VUS, missense mutation of <italic toggle="yes">FGF/FGFR</italic> genes accounts for 91.67% (330/360). (G) The ratio of VUS cases co&#x02010;mutated with <italic toggle="yes">EGFR</italic> is around 49.72% (179/360). (H) The ratio of VUS cases co&#x02010;mutated with <italic toggle="yes">TP53</italic> variant is about 48.33% (174/360).</p></caption><graphic xlink:href="TCA-16-e70016-g005" position="anchor" id="jats-graphic-3"/></fig><p>In the 118 PV cases, <italic toggle="yes">FGF/FGFR</italic> copy number increase is the most frequent one (83.05%, 98/118), including <italic toggle="yes">FGF19</italic>, <italic toggle="yes">FGF4</italic>, <italic toggle="yes">FGF3</italic>, <italic toggle="yes">FGFR1</italic>, and <italic toggle="yes">FGFR2</italic> genes (Figure&#x000a0;<xref rid="tca70016-fig-0001" ref-type="fig">1E</xref>). The second one is <italic toggle="yes">FGFR</italic> gene fusion, accounting for 11.86% (14/118) of 118 cases. <italic toggle="yes">FGFR3&#x02010;TACC3</italic> fusions is detected in more than half of the tissue samples&#x000a0;(57.14%, 8/14, Figure&#x000a0;<xref rid="tca70016-fig-0001" ref-type="fig">1E</xref>). And the third one is <italic toggle="yes">FGFR</italic> gene missense mutation (7.63%, 9/118, Figure&#x000a0;<xref rid="tca70016-fig-0001" ref-type="fig">1E</xref>). Furthermore, the most common co&#x02010;mutation genes are <italic toggle="yes">TP53</italic>, <italic toggle="yes">CCND1</italic>, and <italic toggle="yes">CDKN2</italic>. Interestingly, the findings reveal that <italic toggle="yes">CCND1</italic> amplifications are invariably&#x000a0;accompanied by amplifications in the <italic toggle="yes">FGF19</italic> &#x000a0;gene (100.00%, 43/43).</p><p>Moreover, among the 375 cases within VUS, the majority is missense mutation of <italic toggle="yes">FGF/FGFR</italic> genes (91.67%, 330/360, Figure&#x000a0;<xref rid="tca70016-fig-0001" ref-type="fig">1F</xref>). Cases harbored VUS are most co&#x02010;mutated with <italic toggle="yes">EGFR</italic> (49.72%, 179/360, Figure&#x000a0;<xref rid="tca70016-fig-0001" ref-type="fig">1G</xref>) and <italic toggle="yes">TP53</italic> variant (48.33%, 174/360, Figure&#x000a0;<xref rid="tca70016-fig-0001" ref-type="fig">1H</xref>).</p><p>To sum up, the <italic toggle="yes">FGF/FGFR</italic> alteration mainly arises in squamous cell carcinoma. <italic toggle="yes">FGF/FGFR</italic> copy number increase has priority over other variants in PV samples, while missense mutation is the most common one in VUS cases. Besides, <italic toggle="yes">FGF19</italic> always co&#x02010;amplify with <italic toggle="yes">CCND1</italic> gene in PV cases.</p></sec><sec id="tca70016-sec-0011"><label>3.2</label><title>The Survival and Clinicopathological Characteristics in Surgically Resected Specimens Within <italic toggle="no">
<styled-content style="fixed-case" toggle="no">FGF</styled-content>/<styled-content style="fixed-case" toggle="no">FGFR</styled-content>
</italic> Variant</title><p>Second, to better understand the survival and clinicopathological characteristics in <italic toggle="yes">FGF/FGFR</italic> variant, we analyze 367 surgically resected specimens, including 84 PV and 283 VUS cases. Most PV cases are Sq, while the majority of VUS are Ad (Sq: 61.90%, 52/84, Ad: 85.87%, 243/283, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Table&#x000a0;<xref rid="tca70016-tbl-0001" ref-type="table">1</xref>). The majority of cases haboring PV are&#x000a0;current smokers or ever&#x02010;smokers (PV: 78.57%, 66/84, VUS: 42.05%, 119/283, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Table&#x000a0;<xref rid="tca70016-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="tca70016-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>The clinicopathological characteristics in 367 surgically resected specimens within <italic toggle="no">FGF/FGFR</italic> variant.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total (<italic toggle="yes">n</italic>&#x02009;=&#x02009;367)</th><th align="center" valign="bottom" rowspan="1" colspan="1">PV (<italic toggle="yes">n</italic>&#x02009;=&#x02009;84)</th><th align="center" valign="bottom" rowspan="1" colspan="1">VUS (<italic toggle="yes">n</italic>&#x02009;=&#x02009;283)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.135<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median (IQR)</td><td align="center" valign="top" rowspan="1" colspan="1">63.0 (55.0&#x02013;68.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02264;&#x02009;63.0</td><td align="center" valign="top" rowspan="1" colspan="1">194 (52.86%)</td><td align="center" valign="top" rowspan="1" colspan="1">38 (45.24%)</td><td align="center" valign="top" rowspan="1" colspan="1">156 (55.12%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003e;&#x02009;63.0</td><td align="center" valign="top" rowspan="1" colspan="1">173 (47.14%)</td><td align="center" valign="top" rowspan="1" colspan="1">46 (54.76%)</td><td align="center" valign="top" rowspan="1" colspan="1">127 (44.88%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">146 (39.78%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15.48%)</td><td align="center" valign="top" rowspan="1" colspan="1">133 (47.00%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">221 (60.22%)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (84.52%)</td><td align="center" valign="top" rowspan="1" colspan="1">150 (53.00%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor size</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;1.3 (25th percentile)</td><td align="center" valign="top" rowspan="1" colspan="1">83 (22.62%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (3.57%)</td><td align="center" valign="top" rowspan="1" colspan="1">80 (28.27%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;1.3 and &#x0003c;&#x02009;2.0 (50th percentile)</td><td align="center" valign="top" rowspan="1" colspan="1">79 (21.53%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (9.52%)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (25.09%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;2.0 and &#x0003c;&#x02009;3.5 (75th percentile)</td><td align="center" valign="top" rowspan="1" colspan="1">106 (28.88)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (27.38%)</td><td align="center" valign="top" rowspan="1" colspan="1">83 (29.33%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;3.5</td><td align="center" valign="top" rowspan="1" colspan="1">99 (26.98%)</td><td align="center" valign="top" rowspan="1" colspan="1">50 (59.52%)</td><td align="center" valign="top" rowspan="1" colspan="1">49 (17.31%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Histology</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">263 (71.66%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (23.81%)</td><td align="center" valign="top" rowspan="1" colspan="1">243 (85.87%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Squamous carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">76 (20.71%)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (61.90%)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (8.48%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">28 (7.63%)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (14.29%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (5.65%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Differentiation</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Well differentiated</td><td align="center" valign="top" rowspan="1" colspan="1">54 (14.71%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.38%)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (18.37%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Moderately differentiated</td><td align="center" valign="top" rowspan="1" colspan="1">124 (33.79%)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (20.24%)</td><td align="center" valign="top" rowspan="1" colspan="1">107 (37.81%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Poorly differentiated</td><td align="center" valign="top" rowspan="1" colspan="1">189 (51.50%)</td><td align="center" valign="top" rowspan="1" colspan="1">65 (77.38%)</td><td align="center" valign="top" rowspan="1" colspan="1">124 (43.82%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">pStage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">265 (72.21%)</td><td align="center" valign="top" rowspan="1" colspan="1">44 (52.38%)</td><td align="center" valign="top" rowspan="1" colspan="1">221 (78.09%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">II</td><td align="center" valign="top" rowspan="1" colspan="1">36 (9.81%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15.48%)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (8.13%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">III</td><td align="center" valign="top" rowspan="1" colspan="1">55 (14.99%)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (27.38%)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (11.31%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IV</td><td align="center" valign="top" rowspan="1" colspan="1">11 (3.00%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4.76%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (2.47%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TNM_T stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T1</td><td align="center" valign="top" rowspan="1" colspan="1">252 (68.66%)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (35.71%)</td><td align="center" valign="top" rowspan="1" colspan="1">222 (78.45%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T2</td><td align="center" valign="top" rowspan="1" colspan="1">80 (21.80%)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (40.48%)</td><td align="center" valign="top" rowspan="1" colspan="1">46 (16.25%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T3</td><td align="center" valign="top" rowspan="1" colspan="1">22 (5.99%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15.48%)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (3.18%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T4</td><td align="center" valign="top" rowspan="1" colspan="1">13 (3.54%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (8.33%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2.12%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TNM_N stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.093<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N0</td><td align="center" valign="top" rowspan="1" colspan="1">304 (82.83%)</td><td align="center" valign="top" rowspan="1" colspan="1">63 (75.00%)</td><td align="center" valign="top" rowspan="1" colspan="1">241 (85.16%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N1</td><td align="center" valign="top" rowspan="1" colspan="1">23 (6.27%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (9.52%)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (5.30%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N2</td><td align="center" valign="top" rowspan="1" colspan="1">40 (10.90%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15.48%)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (9.54%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Venous/lymphatic invasion</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.007<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">270 (73.57%)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (61.90%)</td><td align="center" valign="top" rowspan="1" colspan="1">218 (77.03%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Present</td><td align="center" valign="top" rowspan="1" colspan="1">97 (26.43%)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (38.10%)</td><td align="center" valign="top" rowspan="1" colspan="1">65 (22.97%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nerve invasion</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.012<xref rid="tca70016-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">346 (94.28%)</td><td align="center" valign="top" rowspan="1" colspan="1">74 (88.10%)</td><td align="center" valign="top" rowspan="1" colspan="1">272 (96.11%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Present</td><td align="center" valign="top" rowspan="1" colspan="1">21 (5.72%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (11.90%)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (3.89%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pleural invasion</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.066<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">330 (89.92%)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (84.52%)</td><td align="center" valign="top" rowspan="1" colspan="1">259 (91.52%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Present</td><td align="center" valign="top" rowspan="1" colspan="1">37 (10.08%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15.48%)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (8.48%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">STAS</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.017<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">283 (77.11%)</td><td align="center" valign="top" rowspan="1" colspan="1">73 (86.90%)</td><td align="center" valign="top" rowspan="1" colspan="1">210 (74.20%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Present</td><td align="center" valign="top" rowspan="1" colspan="1">84 (22.89%)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (13.10%)</td><td align="center" valign="top" rowspan="1" colspan="1">73 (25.80%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking history</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">182 (49.59%)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (21.43%)</td><td align="center" valign="top" rowspan="1" colspan="1">164 (57.95%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Present</td><td align="center" valign="top" rowspan="1" colspan="1">185 (50.41%)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (78.57%)</td><td align="center" valign="top" rowspan="1" colspan="1">119 (42.05%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PD&#x02010;L1 TPS</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.061<xref rid="tca70016-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">TPS &#x0003c;&#x02009;1%</td><td align="center" valign="top" rowspan="1" colspan="1">242 (65.94%)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (57.14%)</td><td align="center" valign="top" rowspan="1" colspan="1">194 (68.55%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1%&#x02009;&#x02264;&#x02009;TPS&#x02009;&#x0003c;&#x02009;50%</td><td align="center" valign="top" rowspan="1" colspan="1">80 (21.80%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (23.81%)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (21.20%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">TPS&#x02009;&#x02265;&#x02009;50%</td><td align="center" valign="top" rowspan="1" colspan="1">45 (12.26%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (19.05%)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (10.25%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="tca70016-ntgp-0002"><fn id="tca70016-note-0003"><p>
<italic toggle="yes">Note:</italic> Data are presented as <italic toggle="yes">n</italic> (%).</p></fn><fn id="tca70016-note-0004"><p>Abbreviations: IQR, interquartile range; PD&#x02010;L1, programmed cell death protein&#x02010;1 ligand; PV, pathogenic variant; STAS, spread through air spaces; TNM, tumor&#x02010;node&#x02010;metastasis; TPS, tumor proportion scoring; VUS, variant of only uncertain significance.</p></fn><fn id="tca70016-note-0005"><label>
<sup>a</sup>
</label><p>Pearson chi&#x02010;square is used for calculation.</p></fn><fn id="tca70016-note-0006"><label>
<sup>b</sup>
</label><p>Continuity correction is used for calculation.</p></fn></table-wrap-foot></table-wrap><p>Besides, the patients harboring PV tends to present with later pStage (II&#x02010;IV stage), whereas those carrying VUS mostly present with pStage I tumors (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Table&#x000a0;<xref rid="tca70016-tbl-0001" ref-type="table">1</xref>). Additionaly, the tumors harboring PV tend to exhibit&#x000a0;venous/lymphatic invasion (PV: 38.10%, 32/84, VUS: 22.97%, 65/283, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Table&#x000a0;<xref rid="tca70016-tbl-0001" ref-type="table">1</xref>) as well as&#x000a0;nerve invasion (PV: 11.90%, 10/84, VUS: 3.89%, 11/283, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Table&#x000a0;<xref rid="tca70016-tbl-0001" ref-type="table">1</xref>). Nevertheless, the occurrence of spread through air spaces (STAS) is slightly more common in the VUS group than in the PV group (PV: 13.10%, 11/84, VUS: 25.80%, 73/283, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Table&#x000a0;<xref rid="tca70016-tbl-0001" ref-type="table">1</xref>).</p><p>As described, <italic toggle="yes">FGF/FGFR</italic> PV is the primary variant in Sq, while <italic toggle="yes">FGF/FGFR</italic> VUS is the prevalent alteration in the Ad tissues. PV cases have a higher risk of smoking exposure, increased venous/lymphatic invasion, and later pStage. Altogether, these findings indicates that tumors harboring PV tends to be more aggressive in nature.</p></sec><sec id="tca70016-sec-0012"><label>3.3</label><title>
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">FGF</italic>
</styled-content> Variant Is a Predictor of Poor Prognosis</title><p>The effects of <italic toggle="yes">FGF/FGFR</italic> alterations on disease prognosis are elucidated by comprehensive analysis of the <italic toggle="yes">FGF/FGFR</italic> variant subtypes. The findings reveal&#x000a0;that <italic toggle="yes">FGFR</italic> gene fusions are strongly associated with better prognosis, followed by <italic toggle="yes">FGF</italic> amplification and co&#x02010;mutaions in&#x000a0;tumor suppressor genes and <italic toggle="yes">FGF/FGFR</italic> (Figure&#x000a0;<xref rid="tca70016-fig-0002" ref-type="fig">2A</xref> and Table&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S1</xref>, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001). A significantly&#x000a0;shorter overall survival (OS) and DFS are shown in PV cases compared to VUS ones (OS and DFS: <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Figure&#x000a0;<xref rid="tca70016-fig-0002" ref-type="fig">2B,C</xref>). Then we summarize in detail of the 84 <italic toggle="yes">FGF/FGFR</italic> PV cases, which are supposed associated with more aggressive tumor behavior (Figure&#x000a0;<xref rid="tca70016-fig-0002" ref-type="fig">2D</xref>). Among these patients, 19 (22.62%) exhibit disease progression and 14 (16.67%) die&#x000a0;during follow&#x02010;up (median follow&#x02010;up of 28&#x02009;months). The specific factor which accounts for the poor prognosis is still unclear. To better illustrate this point, we compare between two subgroups, which are <italic toggle="yes">FGF</italic> variant (34/84, four cases carry both <italic toggle="yes">FGF</italic> and <italic toggle="yes">FGFR</italic> variants) and <italic toggle="yes">FGFR</italic> alteration (50/84). Though the clinicopathological parameter analysis indicates no big difference between these two groups (Table&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S2</xref>), the survival analysis uncovers a significant differences between the groups. Both OS and DFS are dramatically shorter in <italic toggle="yes">FGF</italic> PV group instead of <italic toggle="yes">FGFR</italic> PV group (OS: <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0164 and DFS: <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0159, Figure&#x000a0;<xref rid="tca70016-fig-0002" ref-type="fig">2E,F</xref>). Univariate analysis of both OS and DFS reveal that the <italic toggle="yes">FGF</italic> PV is a statistically significant prognosis factor (OS: hazard radio (HR) =3.747, 95% CI: 1.173&#x02013;11.970; DFS: HR&#x02009;=&#x02009;3.431, 95% CI: 1.287&#x02013;9.147, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Tables&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S3</xref> and <xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S4</xref>). The multivariate analysis further confirms that the presence of <italic toggle="yes">FGF</italic> PV is an independent prognostic risk factor for NSCLC (OS: HR&#x02009;=&#x02009;3.781, 95% CI: 1.109&#x02013;12.890; DFS: HR&#x02009;=&#x02009;3.340, 95% CI: 1.180&#x02013;9.450, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Figure&#x000a0;<xref rid="tca70016-fig-0002" ref-type="fig">2G,H</xref>).</p><fig position="float" fig-type="FIGURE" id="tca70016-fig-0002"><label>FIGURE 2</label><caption><p>Survival curve shows the shorter OS and DFS in <italic toggle="yes">FGF</italic> PV group compared to <italic toggle="yes">FGFR</italic> PV ones. (A) The summary of <italic toggle="yes">FGF/FGFR</italic> variant subtypes in 367 surgically resected specimens. The variants include <italic toggle="yes">FGF</italic> amplification, <italic toggle="yes">FGF</italic> (single nucleotide variant) SNV, <italic toggle="yes">FGFR</italic> amplification, <italic toggle="yes">FGFR</italic> fusion, <italic toggle="yes">FGFR</italic> SNV, <italic toggle="yes">FGF</italic>&#x02009;+&#x02009;<italic toggle="yes">FGFR</italic> variants, &#x02265;&#x02009;2 <italic toggle="yes">FGFR</italic> variants. (B) The overall survival (OS) is dramatically shorter in pathogenic variant (PV) group in contrast to VUS group. The survival rate is 79.47% in PV group while 95.24% in VUS group (****<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001). (C) The disease&#x02010;free survival (DFS) is dramatically shorter in PV group compared to VUS group. The survival rate is 77.47% in PV group while 94.55% in VUS group (****<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001). (D) The heatmap of clinicopathological features in 84 PV surgically resected specimens, including nineteen parameters. (E) The OS is dramatically shorter in <italic toggle="yes">FGF</italic> PV group in contrast to <italic toggle="yes">FGFR</italic> PV group. The survival rate is 66.21% in <italic toggle="yes">FGF</italic> PV group while 90.49% in <italic toggle="yes">FGFR</italic> PV group (*<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). (F) The DFS is dramatically shorter in <italic toggle="yes">FGF</italic> PV group compared to <italic toggle="yes">FGFR</italic> PV group. The survival rate is 63.75% in <italic toggle="yes">FGF</italic> PV group while 86.57% in <italic toggle="yes">FGFR</italic> PV group (*<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). (G) The multivariate analysis shows the hazard radio (HR) of OS in PV subtype, histology, pStage and venous/lymphatic invasion. The HR in <italic toggle="yes">FGF</italic> PV group is as high as 3.781 (95% CI: 1.109&#x02013;12.890, *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). (H) The multivariate analysis shows the HR of DFS in PV subtype, histology, pStage and venous/lymphatic invasion. The HR in <italic toggle="yes">FGF</italic> PV group is as high as 3.340 (95% CI: 1.180&#x02013;9.450, *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></caption><graphic xlink:href="TCA-16-e70016-g004" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="tca70016-sec-0013"><label>3.4</label><title>Distinct Histological Features associated with <styled-content style="fixed-case" toggle="no">
<italic toggle="no">FGFR</italic>
</styled-content> Alterations</title><p>Although <italic toggle="yes">FGFR</italic> variant is not a predictor for poor prognosis in the group harboring PV, they remain a significant concern due to their potential as promising rug targets. An interesting thing is that <italic toggle="yes">FGFR</italic> gene fusion, ranked as the second alteration in 118 PV cases (11.86%, 14/118), exhibits a distinctive clinicopathological feature. Around 42.86% of <italic toggle="yes">FGFR</italic> gene fusion subtype is <italic toggle="yes">FGFR3&#x02010;TACC3</italic> (6/14, Figure&#x000a0;<xref rid="tca70016-fig-0003" ref-type="fig">3A</xref>). And all these samples harboring the <italic toggle="yes">FGFR3&#x02010;TACC3</italic> subtype display poor differentiation (100%, 6/6). Interestingly, about one&#x02010;third tends to display clear cytoplasm in histology (33.33%, 2/6, Figure&#x000a0;<xref rid="tca70016-fig-0003" ref-type="fig">3B</xref>). In contrast with the other fusion types, <italic toggle="yes">FGFR3&#x02010;TACC3</italic> fusion is tightly related to later TNM_T stage (T2&#x02010;T3: 100.00%, 6/6, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.020, Table&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S5</xref>), and higher risk with cigarette exposure (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Figure&#x000a0;<xref rid="tca70016-fig-0003" ref-type="fig">3C,D</xref> and Table&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S5</xref>).</p><fig position="float" fig-type="FIGURE" id="tca70016-fig-0003"><label>FIGURE 3</label><caption><p>Survival curve shows the shorter OS and DFS in <italic toggle="yes">FGF</italic> PV group compared to <italic toggle="yes">FGFR</italic> PV ones. (A) In 118 PV cases, the proportion of <italic toggle="yes">FGFR</italic> gene fusion is about 11.86% (14/118). The most common <italic toggle="yes">FGFR</italic> gene fusion subtype is <italic toggle="yes">FGFR3&#x02010;TACC3</italic> (42.86%, 6/14). (B) The representative view of clear cytoplasm in <italic toggle="yes">FGFR3&#x02010;TACC3</italic> fusion cases (33.33%, 2/6, scale bar&#x02009;=&#x02009;50&#x02009;&#x003bc;M). (C) In fourteen <italic toggle="yes">FGFR</italic> gene fusion cases, 42.86% is <italic toggle="yes">FGFR3&#x02010;TACC3</italic> fusion with cigarette exposure, 21.43% is other <italic toggle="yes">FGFR</italic> fusion with cigarette exposure, the other 35.71% is other <italic toggle="yes">FGFR</italic> fusion without cigarette exposure. (D) There is no significant difference of cigarette pack&#x02010;year between <italic toggle="yes">FGFR3&#x02010;TACC3</italic> fusion and other <italic toggle="yes">FGFR</italic> fusion cases (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.2188).</p></caption><graphic xlink:href="TCA-16-e70016-g001" position="anchor" id="jats-graphic-7"/></fig></sec><sec id="tca70016-sec-0014"><label>3.5</label><title>Association of Co&#x02010;mutant Genes and FGF/FGFR Variants With Smoking Status and Poor Prognostic Risk</title><p>Furthermore, the co&#x02010;mutation genes also act as the risk factor involved in <italic toggle="yes">FGF/FGFR</italic> alteration. As we mentioned above, cigarette exposure plays an important role in <italic toggle="yes">FGF/FGFR</italic> variant samples (50.41%, 185/367), especially PV group (78.57%, 66/84, Table&#x000a0;<xref rid="tca70016-tbl-0001" ref-type="table">1</xref>). Interestingly, among some paired variants, the smoking status is tightly linked to poor morphology features. For example, the majority of cases harboring PV and <italic toggle="yes">CCND1/FGF19</italic> co&#x02010;amplifications include smokers or ever smokers&#x000a0;(78.79%, 26/33, Figure&#x000a0;<xref rid="tca70016-fig-0004" ref-type="fig">4A</xref>), and the majority of tissues exhibit&#x000a0;poor differentiation (88.46%, 23/26, Figure&#x000a0;<xref rid="tca70016-fig-0004" ref-type="fig">4B</xref>). Besides, another co&#x02010;mutant gene <italic toggle="yes">KRAS</italic>, which occupies around 9.81% (36/367, Figure&#x000a0;<xref rid="tca70016-fig-0004" ref-type="fig">4C</xref>) in surgically resected specimens, is proved to have high ratio of cigarette exposure (80.56%, 29/36, Figure&#x000a0;<xref rid="tca70016-fig-0004" ref-type="fig">4C</xref>). Among these smokers, 75.86% patients are found within poor differentiation (22/29, Figure&#x000a0;<xref rid="tca70016-fig-0004" ref-type="fig">4D</xref>). In survival analysis, shorter OS and DFS are observed in <italic toggle="yes">KRAS</italic> co&#x02010;mutation group (PV: Figure&#x000a0;<xref rid="tca70016-fig-0004" ref-type="fig">4E,F</xref>, VUS: Figure&#x000a0;<xref rid="tca70016-fig-0004" ref-type="fig">4G,H</xref>). Univariate analysis detects that <italic toggle="yes">KRAS</italic> PV is a predictor for poor DFS and not yet OS (DFS: HR&#x02009;=&#x02009;3.279, 95% CI: 1.076&#x02013;9.991, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Tables&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S3</xref> and <xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S4</xref>). And multivariate analysis proves that <italic toggle="yes">KRAS</italic> PV is an independent risk factor (DFS: HR&#x02009;=&#x02009;6.790, 95% CI: 1.889&#x02013;24.400, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Figure&#x000a0;<xref rid="tca70016-fig-0004" ref-type="fig">4I</xref>).</p><fig position="float" fig-type="FIGURE" id="tca70016-fig-0004"><label>FIGURE 4</label><caption><p>Co&#x02010;mutation genes reveal the smoking and poor prognosis risk involved in <italic toggle="yes">FGF/FGFR</italic> variant. (A) In 367 surgically resected specimens, <italic toggle="yes">CCND1/FGF19</italic> co&#x02010;amplification accounts for 8.99% (33/367). The priority of <italic toggle="yes">CCND1/FGF19</italic> co&#x02010;amplification PV cases is smoker or ever smoker (78.79%, 26/33). (B) Approximately, 88.46% cases exhibit poor differentiation (23/26). (C) Co&#x02010;mutant gene <italic toggle="yes">KRAS</italic> occupies around 9.81% in 367 surgically resected specimens (36/367). These cases are proved to have high ratio of cigarette exposure (80.56%, 29/36). (D) The 75.86% among these smokers have poor differentiation (22/29). (E) In survival analysis, shorter OS is observed in within <italic toggle="yes">KRAS</italic> co&#x02010;mutation PV group. The survival rate is 50.00% in <italic toggle="yes">KRAS</italic> PV group while 70.40% in other PV group (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.1478). (F) Shorter DFS is observed in within <italic toggle="yes">KRAS</italic> co&#x02010;mutation PV group. (G) Shorter OS is observed in within <italic toggle="yes">KRAS</italic> co&#x02010;mutation group. The survival rate is 87.24% in <italic toggle="yes">KRAS</italic> VUS group while 96.19% in other VUS group (*<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). (H) Shorter DFS is observed in within <italic toggle="yes">KRAS</italic> co&#x02010;mutation group. The survival rate is 75.59% in <italic toggle="yes">KRAS</italic> VUS group while 96.49% in other VUS group (****<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001). (I) The multivariate analysis shows the HR of DFS in PV subtype, pStage and venous/lymphatic invasion. The HR in <italic toggle="yes">KRAS</italic> PV group is as high as 6.790 (95% CI: 1.889&#x02013;24.400, **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p></caption><graphic xlink:href="TCA-16-e70016-g006" position="anchor" id="jats-graphic-9"/></fig><p>In sum, neighboring gene mutation on 11p13 region (<italic toggle="yes">CCND1/FGF19</italic> co&#x02010;amplification) is a gene event tightly related to smoking and poor differentiation. <italic toggle="yes">KRAS</italic> co&#x02010;mutation is proved to be an independent risk factor of poor DFS in PV patients.</p></sec><sec id="tca70016-sec-0015"><label>3.6</label><title>
<italic toggle="yes">FGF/FGFR</italic> and <italic toggle="yes">NOTCH1/RB1</italic> Co&#x02010;Mutations Promote an Inflammatory Microenvironment, Contributing to a &#x0201c;Hot&#x0201d; Tumor Phenotype</title><p>Ultimately, PV group HE slides are collected and analyzed by AI&#x02010;based model to reveal the microenvironment features. Interestingly, compared to the progressed cases, the non&#x02010;progressed ones have higher level of TLS formation, including both immature and mature ones (Figure&#x000a0;<xref rid="tca70016-fig-0005" ref-type="fig">5A</xref>). While there is no big difference of TLS number between cases within <italic toggle="yes">FGF</italic> and <italic toggle="yes">FGFR</italic> variants (Figure&#x000a0;<xref rid="tca70016-fig-0005" ref-type="fig">5B</xref>). It seems that the co&#x02010;mutant genes account for microenvironment remodeling in patients with good prognosis. According to statistics, co&#x02010;mutations in <italic toggle="yes">FGF/FGFR</italic> and <italic toggle="yes">NOTCH1</italic> (3.81%, 14/367, 8 PV and 6 VUS) are associated with significantly higher PD&#x02010;L1 expression ratio compared to cases without <italic toggle="yes">NOTCH1</italic> co&#x02010;mutations (with <italic toggle="yes">NOTCH1</italic> co&#x02010;mutations: Tumor proportion score (TPS)&#x02009;&#x02265;&#x02009;50% 28.57%, 4/14; others: TPS&#x02009;&#x02265;&#x02009;50% 11.61%, 41/353, Figure&#x000a0;<xref rid="tca70016-fig-0005" ref-type="fig">5C</xref>). <italic toggle="yes">NOTCH1</italic> The Sq samples with <italic toggle="yes">NOTCH1</italic> co&#x02010;mutations&#x000a0;have higher proportion of PD&#x02010;L1 expression (with <italic toggle="yes">NOTCH1</italic> co&#x02010;mutations TPS&#x02009;&#x02265;&#x02009;50% 33.33%, 4/12; others: TPS&#x02009;&#x02265;&#x02009;50% 25.00%, 16/24, Figure&#x000a0;<xref rid="tca70016-fig-0005" ref-type="fig">5D</xref>). Inside the fourteen <italic toggle="yes">NOTCH1</italic> co&#x02010;mutant cases, we divided and compared between within <italic toggle="yes">RB1</italic> variant group (4/14) and without <italic toggle="yes">RB1</italic> variant group (10/14). Remarkedly, the <italic toggle="yes">FGF/FGFR1/NOTCH1</italic> within <italic toggle="yes">RB1</italic> variant group has a dramatically higher inner&#x02010;tumor CD8+ T cell infiltration (Figure&#x000a0;<xref rid="tca70016-fig-0005" ref-type="fig">5E,F</xref>), following more CD8+PD&#x02010;1&#x02010;LAG3&#x02010; non&#x02010;exhausted T cells (Figure&#x000a0;<xref rid="tca70016-fig-0005" ref-type="fig">5E,G</xref>) and CD8+PD&#x02010;1+LAG3&#x02010; exhausted T cells (Figure&#x000a0;<xref rid="tca70016-fig-0005" ref-type="fig">5E,H</xref>). Furthermore, the CD69+CD103+ tissue&#x02010;resident memory T (T<sub>RM</sub>) cells, the important drivers of inflammation, are at significant high frequencies in <italic toggle="yes">FGF/FGFR1/NOTCH1</italic> within <italic toggle="yes">RB1</italic> variant group. (Figure&#x000a0;<xref rid="tca70016-fig-0005" ref-type="fig">5E,I</xref>). Thus, it is obvious that the <italic toggle="yes">FGF/FGFR1/NOTCH1</italic> within <italic toggle="yes">RB1</italic> variant subtype tends to recruit an inflamed immune microenvironment, which might be a potential benefit population for anti&#x02010;PD&#x02010;1 therapy. This might support a pro&#x02010;immunotherapy role of <italic toggle="yes">NOTCH1</italic> gene in <italic toggle="yes">FGF/FGFR</italic> alteration cases.</p><fig position="float" fig-type="FIGURE" id="tca70016-fig-0005"><label>FIGURE 5</label><caption><p>(A) <styled-content style="fixed-case" toggle="no">
<italic toggle="no">AI</italic>
</styled-content>&#x02010;based model detects both high immature and mature TLS numbers in progressed case rather than non&#x02010;progressed ones in PV group (*<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). (B) There is no significant difference between <italic toggle="yes">FGFR</italic> and <italic toggle="yes">FGF</italic> variant cases for both immature (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.2135) and mature TLS numbers (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.3581). (C) <italic toggle="yes">FGF/FGFR</italic> co&#x02010;mutant within <italic toggle="yes">NOTCH1</italic> accounts for 3.81% (14/367) in 367 surgically resected specimens, including 8 PV and 6 VUS cases. Co&#x02010;mutant within <italic toggle="yes">NOTCH1</italic> samples has an obvious high PD&#x02010;L1 expression ratio compared to without <italic toggle="yes">NOTCH1</italic> cases (<italic toggle="yes">NOTCH1</italic>: TPS&#x02009;&#x02265;&#x02009;50% 28.57%, 4/14; others: TPS&#x02009;&#x02265;&#x02009;50% 11.61%, 41/353). (D) Within <italic toggle="yes">NOTCH1</italic> Sq cases also has high proportion of PD&#x02010;L1 expression (<italic toggle="yes">NOTCH1</italic>: TPS&#x02009;&#x02265;&#x02009;50% 33.33%, 4/12; others: TPS&#x02009;&#x02265;&#x02009;50% 25.00%, 16/24). Inside the fourteen <italic toggle="yes">NOTCH1</italic> co&#x02010;mutant cases, remarkedly, the <italic toggle="yes">FGF/FGFR1/NOTCH1</italic> within <italic toggle="yes">RB1</italic> variant group has a dramatically higher inner&#x02010;tumor CD8+ T cell infiltration [(E) left column, CD8: Orange, pan&#x02010;CK: Gray, scale bar&#x02009;=&#x02009;50&#x02009;&#x003bc;M; (F) **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01]. More inner&#x02010;tumor CD8+PD&#x02010;1&#x02010;LAG3&#x02010; non&#x02010;exhausted T cells intensity is in within <italic toggle="yes">RB1</italic> variant group [E middle column, no green and magenta, PD&#x02010;1: Green, L AG3: Magenta, scale bar&#x02009;=&#x02009;50&#x02009;&#x003bc;M; (G) ****<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001] and CD8+PD&#x02010;1+LAG3&#x02010; exhausted T cells [E middle column, green and no magenta, PD&#x02010;1: Green, L AG3: Magenta, scale bar&#x02009;=&#x02009;50&#x02009;&#x003bc;M; (H) **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01]. Furthermore, the inner&#x02010;tumor CD69+CD103+ tissue&#x02010;resident memory T (T<sub>RM</sub>) cells, are at significant high frequencies in <italic toggle="yes">FGF/FGFR1/NOTCH1</italic> within <italic toggle="yes">RB1</italic> variant group. [E right column, yellow and red, CD69: Yellow, CD103: Red, scale bar&#x02009;=&#x02009;50&#x02009;&#x003bc;M; (I) *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05].</p></caption><graphic xlink:href="TCA-16-e70016-g002" position="anchor" id="jats-graphic-11"/></fig></sec></sec><sec sec-type="discussion" id="tca70016-sec-0016"><label>4</label><title>Discussion</title><p>Recently, FGF ligands [<xref rid="tca70016-bib-0011" ref-type="bibr">11</xref>, <xref rid="tca70016-bib-0012" ref-type="bibr">12</xref>, <xref rid="tca70016-bib-0013" ref-type="bibr">13</xref>, <xref rid="tca70016-bib-0014" ref-type="bibr">14</xref>, <xref rid="tca70016-bib-0015" ref-type="bibr">15</xref>] and their receptors [<xref rid="tca70016-bib-0013" ref-type="bibr">13</xref>, <xref rid="tca70016-bib-0014" ref-type="bibr">14</xref>, <xref rid="tca70016-bib-0015" ref-type="bibr">15</xref>, <xref rid="tca70016-bib-0016" ref-type="bibr">16</xref>, <xref rid="tca70016-bib-0017" ref-type="bibr">17</xref>, <xref rid="tca70016-bib-0018" ref-type="bibr">18</xref>] can serve as potential biomarkers&#x000a0;in lung cancer. Additionally, treatment with FGFR inhibitors, including pemigatinib and erdafitinib can increases the survival rate of Non&#x02013;small cell lung cancer (NSCLC) patients [<xref rid="tca70016-bib-0018" ref-type="bibr">18</xref>, <xref rid="tca70016-bib-0026" ref-type="bibr">26</xref>]. The basic FGFR family has four active members including FGFR1, FGFR2, FGFR3, and FGFR4. Their activation plays a crucial role in cancer initiation [<xref rid="tca70016-bib-0019" ref-type="bibr">19</xref>, <xref rid="tca70016-bib-0020" ref-type="bibr">20</xref>, <xref rid="tca70016-bib-0021" ref-type="bibr">21</xref>, <xref rid="tca70016-bib-0022" ref-type="bibr">22</xref>, <xref rid="tca70016-bib-0023" ref-type="bibr">23</xref>, <xref rid="tca70016-bib-0024" ref-type="bibr">24</xref>, <xref rid="tca70016-bib-0025" ref-type="bibr">25</xref>]. However, the contributions of the <italic toggle="yes">FGF/FGFR</italic> signally pathway to patient&#x000a0;survival, clinicopathological features, and characteristics of the tumor microenvironment remain poorly understood. Especially, the roles of <italic toggle="yes">FGF</italic> alterations have been scarcely investigated to date.</p><p>A total 4656 lung cancer cases examined by NGS are included in this study. Compared to the previous pan&#x02010;cancer study, [<xref rid="tca70016-bib-0030" ref-type="bibr">30</xref>, <xref rid="tca70016-bib-0031" ref-type="bibr">31</xref>] we provide a comprehensive analysis about <italic toggle="yes">FGF/FGFR</italic> alteration in large&#x02010;scale Asian NSCLC cohort. About 10.27% (478/4656) patients harboring <italic toggle="yes">FGF/FGFR</italic> alteration are discussed on variant diversity in detail. We first find the <italic toggle="yes">FGF/FGFR</italic> variant is mainly in squamous cell carcinoma (Sq) rather than adenocarcinoma (Ad), which reveals a potential benefit of Sq from inhibitor treatment like pemigatinib and erdafitinib [<xref rid="tca70016-bib-0018" ref-type="bibr">18</xref>, <xref rid="tca70016-bib-0026" ref-type="bibr">26</xref>]. Then, the obvious higher risk of smoking exposure, invasion behavior, and later pStage all promise an aggressive behavior in PV group. A significant shorter OS and DFS are shown in PV cases compared to VUS ones (Figure&#x000a0;<xref rid="tca70016-fig-0002" ref-type="fig">2B,C</xref>). However, different variant subtypes might contribute to different outcome. Hence, we analyze the variant subtypes in depth. <italic toggle="yes">FGFR</italic> fusion seems to have better prognosis, while <italic toggle="yes">FGF</italic> amplification and <italic toggle="yes">FGF</italic>/<italic toggle="yes">FGFR</italic> combined alteration tumor suppressor gene co&#x02010;mutation (Figure&#x000a0;<xref rid="tca70016-fig-0002" ref-type="fig">2A</xref> and Table&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S1</xref>, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001).</p><p>Survival analysis reveal that <italic toggle="yes">FGF</italic> PV is an independent factor for poor prognosis, with a high hazard ratio for both OS and DFS. Conversely, <italic toggle="yes">FGFR</italic> variant is not a predictor for poor prognosis in PV group. The <italic toggle="yes">FGF/FGFR</italic> novel drug development is better to pay more attention on <italic toggle="yes">FGF</italic> variant. Besides, <italic toggle="yes">FGFR3&#x02010;TACC3</italic> fusion has a considerable ratio of the squamous carcinoma (83.33%, 5/6, Table&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S5</xref>), which may explain why the smoking ratio is in common.</p><p>Furthermore, despite the variant diversity, we also talk about the co&#x02010;mutation diversity in <italic toggle="yes">FGF/FGFR</italic> signaling alteration. The <italic toggle="yes">FGF19/CCND1</italic> co&#x02010;amplify is a smoking&#x02010;related event and leads to poor differentiation. This provides a latent drug target of neighboring genes on 11p13 region. Another similar pair is <italic toggle="yes">FGF</italic>/<italic toggle="yes">FGFR</italic> and <italic toggle="yes">KRAS</italic>. Co&#x02010;mutation gene <italic toggle="yes">KRAS</italic> reveals the high smoking exposure and poor prognosis risk in <italic toggle="yes">FGF/FGFR</italic> variant. <italic toggle="yes">FGF</italic>/<italic toggle="yes">FGFR/KRAS</italic> co&#x02010;mutation is a remarkable and independent prognosis factor in short DFS. Smokers might take advantage from integrating <italic toggle="yes">FGF/FGFR</italic> and <italic toggle="yes">KRAS</italic> target therapy.</p><p>Moreover, the non&#x02010;progressed cases display a high level of TLS formation, including both immature and mature ones. While there is no big difference of TLS number between cases within <italic toggle="yes">FGF</italic> and <italic toggle="yes">FGFR</italic> variant, which indicates the role of co&#x02010;mutation gene on microenvironment remodeling in patients with good prognosis. High PD&#x02010;L1 is frequent in <italic toggle="yes">FGF/FGFR</italic> and <italic toggle="yes">NOTCH1</italic> co&#x02010;mutant group, which implies the potential sensitivity to immunotherapy. To better uncover the potential effect of <italic toggle="yes">NOTCH1</italic> co&#x02010;mutation on immunotherapy, we also describe the surrounding microenvironment. The <italic toggle="yes">FGF/FGFR1/NOTCH1</italic> within <italic toggle="yes">RB1</italic> variant group has a dramatically inflamed microenvironment, showing higher inner&#x02010;tumor CD8+ T cell infiltration. Especially, the CD8+PD&#x02010;1+LAG3&#x02010; exhausted T cells are predominant, which suggests a potential benefit from anti&#x02010;PD&#x02010;1 therapy [<xref rid="tca70016-bib-0032" ref-type="bibr">32</xref>, <xref rid="tca70016-bib-0033" ref-type="bibr">33</xref>, <xref rid="tca70016-bib-0034" ref-type="bibr">34</xref>, <xref rid="tca70016-bib-0035" ref-type="bibr">35</xref>]. Furthermore, this group recruits the CD69+CD103+ tissue&#x02010;resident memory T (T<sub>RM</sub>) cells at a high frequency. These cells help form an inflamed microenvironment contributed to favorable clinical outcome [<xref rid="tca70016-bib-0036" ref-type="bibr">36</xref>, <xref rid="tca70016-bib-0037" ref-type="bibr">37</xref>, <xref rid="tca70016-bib-0038" ref-type="bibr">38</xref>]. According to the clinicopathological analysis, <italic toggle="yes">NOTCH1</italic> co&#x02010;mutation comes across with an astonishing high smoking exposure ratio (92.86%, 13/14) and high Sq ratio (85.71%, 12/14, Table&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S6</xref>). The smoking statues might promote inflamed microenvironment formation, which is more susceptible to immunotherapy [<xref rid="tca70016-bib-0039" ref-type="bibr">39</xref>, <xref rid="tca70016-bib-0040" ref-type="bibr">40</xref>]. Simultaneously, the <italic toggle="yes">RB1</italic> gene itself would enhance sensitivity to immunotherapy by impacting immunological features and remodeling microenvironment [<xref rid="tca70016-bib-0041" ref-type="bibr">41</xref>].</p><p>To be honest, we still have some limitations. The survival analysis also reveals a favorable prognosis tendency in <italic toggle="yes">NOTCH1</italic> co&#x02010;mutant group rather than others (Figure&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S1A&#x02013;D</xref>). But the follow&#x02010;up time of <italic toggle="yes">NOTCH1</italic> co&#x02010;mutant group is too short to drive a solid conclusion, because most cases just receive surgery in 2023. In addition, the <italic toggle="yes">FGF/FGFR/NOTCH1</italic> within <italic toggle="yes">RB1</italic> variant group shows a slightly high ratio of STAS, the mechanism remains unknown (Table&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S7</xref>). In addition, <italic toggle="yes">FGFR</italic> fusion also show a better outcome tendency compared to <italic toggle="yes">FGFR</italic> no fusion group, especially the <italic toggle="yes">FGFR1</italic> amplification group (Figure&#x000a0;<xref rid="tca70016-supitem-0001" ref-type="supplementary-material">S1E,F</xref>). The follow&#x02010;up time for some cases is too short to draw a solid conclusion. These will be the future direction when we have longer observation time and enroll enough cases.</p><p>In sum, we summarized the mutation diversity of <italic toggle="yes">FGF/FGFR</italic> alteration in NSCLC, and further analysis of the survival and clinicopathological indicators in different variant subgroups. Besides, we analyzed the co&#x02010;mutation genes of <italic toggle="yes">FGF/FGFR</italic> variant to enrich the knowledge of <italic toggle="yes">FGF/FGFR</italic> signaling.</p></sec><sec sec-type="conclusions" id="tca70016-sec-0017"><label>5</label><title>Conclusion</title><p>Given the above, our study provides a comprehensive analysis about <italic toggle="yes">FGF/FGFR</italic> alteration in a large&#x02010;scale NSCLC cohort of Asian patients with NSCLC, and it is observed that <italic toggle="yes">FGF/FGFR</italic> alterations are more prevalent&#x000a0;in squamous cell carcinoma. Both <italic toggle="yes">FGF</italic> PV and <italic toggle="yes">KRAS</italic> mutations act as the independent risk factors of poor prognosis, and combined against these targets can significantly improve patient outcomes. To the best of our knowledge, this is the first report to describe the role of <italic toggle="yes">NOTCH1/RB1</italic> co&#x02010;mutations in the development of an inflammatory microenvironment, suggesting &#x000a0;the potential benefits of immunotherapy in these cases.</p></sec><sec id="tca70016-sec-0018"><title>Author Contributions</title><p>
<bold>Ziling Huang:</bold> conceptualization, funding acquisition, formal analysis, investigation, methodology, and writing &#x02013; original draft. <bold>Leyao Li and Xu Cai:</bold> data curation, formal analysis, investigation, methodology, and validation. <bold>Shen Wang:</bold> methodology. <bold>Yun Jia:</bold> methodology. <bold>Yuan Li:</bold> conceptualization, funding acquisition, project administration, supervision, and writing &#x02013; review and editing.</p></sec><sec id="tca70016-sec-0021"><title>Ethics Statement</title><p>This retrospective study was approved by The Ethics Committee of the Fudan University Shanghai Cancer Center (No. 050432&#x02010;4&#x02010;2307E). Written informed consent was obtained from patients prior to study commencement.</p></sec><sec sec-type="COI-statement" id="tca70016-sec-0019"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="tca70016-supitem-0001" position="float" content-type="local-data"><caption><p>
Data S1.
</p></caption><media xlink:href="TCA-16-e70016-s001.docx"/></supplementary-material></sec></body><back><ack id="tca70016-sec-0020"><title>Acknowledgments</title><p>We are grateful to Alpha X Biotech (Beijing) Co. Ltd. for the technical assistance and support in mIHC design and image analysis. We greatly appreciate the technical assistance about optimizing YOLOv8 AI model by Dr. Shen Wang. This paper has been uploaded to ENTER PREPRINT SERVER as a preprint: <ext-link xlink:href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4810688" ext-link-type="uri">https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4810688</ext-link>. The authors thank TopEdit for English language editing.</p></ack><sec sec-type="data-availability" id="tca70016-sec-0023"><title>Data Availability Statement</title><p>All datasets included in the current study are available from the corresponding author on reasonable request.</p></sec><ref-list content-type="cited-references" id="tca70016-bibl-0001"><title>References</title><ref id="tca70016-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="tca70016-cit-0001">
<string-name>
<given-names>M.</given-names>
<surname>Cao</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Sun</surname>
</string-name>, and <string-name>
<given-names>W.</given-names>
<surname>Chen</surname>
</string-name>, &#x0201c;<article-title>Cancer Burden of Major Cancers in China: A Need for Sustainable Actions</article-title>,&#x0201d; <source>Cancer Communications</source>
<volume>40</volume> (<year>2020</year>): <fpage>205</fpage>&#x02013;<lpage>210</lpage>, <pub-id pub-id-type="doi">10.1002/cac2.12025</pub-id>.<pub-id pub-id-type="pmid">32359212</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="tca70016-cit-0002">
<string-name>
<given-names>R. L.</given-names>
<surname>Siegel</surname>
</string-name>, <string-name>
<given-names>K. D.</given-names>
<surname>Miller</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Jemal</surname>
</string-name>, &#x0201c;<article-title>Cancer Statistics, 2020</article-title>,&#x0201d; <source>CA: a Cancer Journal for Clinicians</source>
<volume>70</volume> (<year>2020</year>): <fpage>7</fpage>&#x02013;<lpage>30</lpage>, <pub-id pub-id-type="doi">10.3322/caac.21590</pub-id>.<pub-id pub-id-type="pmid">31912902</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="tca70016-cit-0003">
<string-name>
<given-names>R. L.</given-names>
<surname>Siegel</surname>
</string-name>, <string-name>
<given-names>A. N.</given-names>
<surname>Giaquinto</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Jemal</surname>
</string-name>, &#x0201c;<article-title>Cancer Statistics, 2024</article-title>,&#x0201d; <source>CA: A Cancer Journal for Clinicians</source>
<volume>74</volume> (<year>2024</year>): <fpage>12</fpage>&#x02013;<lpage>49</lpage>, <pub-id pub-id-type="doi">10.3322/caac.21820</pub-id>.<pub-id pub-id-type="pmid">38230766</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="tca70016-cit-0004">
<string-name>
<given-names>W.</given-names>
<surname>Cao</surname>
</string-name>, <string-name>
<given-names>H. D.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>Y. W.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Li</surname>
</string-name>, and <string-name>
<given-names>W. Q.</given-names>
<surname>Chen</surname>
</string-name>, &#x0201c;<article-title>Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020</article-title>,&#x0201d; <source>Chinese Medical Journal</source>
<volume>134</volume> (<year>2021</year>): <fpage>783</fpage>&#x02013;<lpage>791</lpage>, <pub-id pub-id-type="doi">10.1097/CM9.0000000000001474</pub-id>.<pub-id pub-id-type="pmid">33734139</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="tca70016-cit-0005">
<string-name>
<given-names>M.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>R. S.</given-names>
<surname>Herbst</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Boshoff</surname>
</string-name>, &#x0201c;<article-title>Toward Personalized Treatment Approaches for Non&#x02010;Small&#x02010;Cell Lung Cancer</article-title>,&#x0201d; <source>Nature Medicine</source>
<volume>27</volume> (<year>2021</year>): <fpage>1345</fpage>&#x02013;<lpage>1356</lpage>, <pub-id pub-id-type="doi">10.1038/s41591-021-01450-2</pub-id>.</mixed-citation></ref><ref id="tca70016-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="tca70016-cit-0006">
<string-name>
<given-names>C.</given-names>
<surname>Xia</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Dong</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Li</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants</article-title>,&#x0201d; <source>Chinese Medical Journal</source>
<volume>135</volume> (<year>2022</year>): <fpage>584</fpage>&#x02013;<lpage>590</lpage>, <pub-id pub-id-type="doi">10.1097/CM9.0000000000002108</pub-id>.<pub-id pub-id-type="pmid">35143424</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="tca70016-cit-0007">
<string-name>
<given-names>E. N.</given-names>
<surname>Imyanitov</surname>
</string-name>, <string-name>
<given-names>A. G.</given-names>
<surname>Iyevleva</surname>
</string-name>, and <string-name>
<given-names>E. V.</given-names>
<surname>Levchenko</surname>
</string-name>, &#x0201c;<article-title>Molecular Testing and Targeted Therapy for Non&#x02010;Small Cell Lung Cancer: Current Status and Perspectives</article-title>,&#x0201d; <source>Critical Reviews in Oncology/Hematology</source>
<volume>157</volume> (<year>2021</year>): <elocation-id>103194</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.critrevonc.2020.103194</pub-id>.<pub-id pub-id-type="pmid">33316418</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="tca70016-cit-0008">
<string-name>
<given-names>S.</given-names>
<surname>Jonna</surname>
</string-name> and <string-name>
<given-names>D. S.</given-names>
<surname>Subramaniam</surname>
</string-name>, &#x0201c;<article-title>Molecular Diagnostics and Targeted Therapies in Non&#x02010;Small Cell Lung Cancer (NSCLC): An Update</article-title>,&#x0201d; <source>Discovery Medicine</source>
<volume>27</volume> (<year>2019</year>): <fpage>167</fpage>&#x02013;<lpage>170</lpage>.<pub-id pub-id-type="pmid">31095926</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="tca70016-cit-0009">
<string-name>
<given-names>M.</given-names>
<surname>Nagasaka</surname>
</string-name> and <string-name>
<given-names>S. M.</given-names>
<surname>Gadgeel</surname>
</string-name>, &#x0201c;<article-title>Role of Chemotherapy and Targeted Therapy in Early&#x02010;Stage Non&#x02010;Small Cell Lung Cancer</article-title>,&#x0201d; <source>Expert Review of Anticancer Therapy</source>
<volume>18</volume> (<year>2018</year>): <fpage>63</fpage>&#x02013;<lpage>70</lpage>, <pub-id pub-id-type="doi">10.1080/14737140.2018.1409624</pub-id>.<pub-id pub-id-type="pmid">29168933</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="tca70016-cit-0010">
<string-name>
<given-names>L.</given-names>
<surname>Osmani</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Askin</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Gabrielson</surname>
</string-name>, and <string-name>
<given-names>Q. K.</given-names>
<surname>Li</surname>
</string-name>, &#x0201c;<article-title>Current WHO Guidelines and the Critical Role of Immunohistochemical Markers in the Subclassification of Non&#x02010;Small Cell Lung Carcinoma (NSCLC): Moving From Targeted Therapy to Immunotherapy</article-title>,&#x0201d; <source>Seminars in Cancer Biology</source>
<volume>52</volume> (<year>2018</year>): <fpage>103</fpage>&#x02013;<lpage>109</lpage>, <pub-id pub-id-type="doi">10.1016/j.semcancer.2017.11.019</pub-id>.<pub-id pub-id-type="pmid">29183778</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="tca70016-cit-0011">
<string-name>
<given-names>D. G.</given-names>
<surname>Brownfield</surname>
</string-name>, <string-name>
<given-names>A. D.</given-names>
<surname>de Arce</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Ghelfi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Gillich</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Desai</surname>
</string-name>, and <string-name>
<given-names>M. A.</given-names>
<surname>Krasnow</surname>
</string-name>, &#x0201c;<article-title>Alveolar Cell Fate Selection and Lifelong Maintenance of AT2 Cells by FGF Signaling</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>13</volume> (<year>2022</year>): <fpage>7137</fpage>, <pub-id pub-id-type="doi">10.1038/s41467-022-34059-1</pub-id>.</mixed-citation></ref><ref id="tca70016-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="tca70016-cit-0012">
<string-name>
<given-names>S.</given-names>
<surname>Danopoulos</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Shiosaki</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Al Alam</surname>
</string-name>, &#x0201c;<article-title>FGF Signaling in Lung Development and Disease: Human Versus Mouse</article-title>,&#x0201d; <source>Frontiers in Genetics</source>
<volume>10</volume> (<year>2019</year>): <elocation-id>170</elocation-id>, <pub-id pub-id-type="doi">10.3389/fgene.2019.00170</pub-id>.<pub-id pub-id-type="pmid">30930931</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="tca70016-cit-0013">
<string-name>
<given-names>M.</given-names>
<surname>Katoh</surname>
</string-name> and <string-name>
<given-names>H.</given-names>
<surname>Nakagama</surname>
</string-name>, &#x0201c;<article-title>FGF Receptors: Cancer Biology and Therapeutics</article-title>,&#x0201d; <source>Medicinal Research Reviews</source>
<volume>34</volume> (<year>2014</year>): <fpage>280</fpage>&#x02013;<lpage>300</lpage>, <pub-id pub-id-type="doi">10.1002/med.21288</pub-id>.<pub-id pub-id-type="pmid">23696246</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="tca70016-cit-0014">
<string-name>
<given-names>L.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Zheng</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>FGF/FGFR Signaling: From Lung Development to Respiratory Diseases</article-title>,&#x0201d; <source>Cytokine and Growth Factor Reviews</source>
<volume>62</volume> (<year>2021</year>): <fpage>94</fpage>&#x02013;<lpage>104</lpage>, <pub-id pub-id-type="doi">10.1016/j.cytogfr.2021.09.002</pub-id>.<pub-id pub-id-type="pmid">34593304</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="tca70016-cit-0015">
<string-name>
<given-names>Y.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Lu</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>du</surname>
</string-name>, &#x0201c;<article-title>FGF/FGFR Signaling Pathway Involved Resistance in Various Cancer Types</article-title>,&#x0201d; <source>Journal of Cancer</source>
<volume>11</volume> (<year>2020</year>): <fpage>2000</fpage>&#x02013;<lpage>2007</lpage>, <pub-id pub-id-type="doi">10.7150/jca.40531</pub-id>.<pub-id pub-id-type="pmid">32127928</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="tca70016-cit-0016">
<string-name>
<given-names>T.</given-names>
<surname>Volckaert</surname>
</string-name> and <string-name>
<given-names>S. P.</given-names>
<surname>De Langhe</surname>
</string-name>, &#x0201c;<article-title>Wnt and FGF Mediated Epithelial&#x02010;Mesenchymal Crosstalk During Lung Development</article-title>,&#x0201d; <source>Developmental Dynamics</source>
<volume>244</volume> (<year>2015</year>): <fpage>342</fpage>&#x02013;<lpage>366</lpage>, <pub-id pub-id-type="doi">10.1002/dvdy.24234</pub-id>.<pub-id pub-id-type="pmid">25470458</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="tca70016-cit-0017">
<string-name>
<given-names>M.</given-names>
<surname>Katoh</surname>
</string-name>, &#x0201c;<article-title>FGFR Inhibitors: Effects on Cancer Cells, Tumor Microenvironment and Whole&#x02010;Body Homeostasis (Review)</article-title>,&#x0201d; <source>International Journal of Molecular Medicine</source>
<volume>38</volume> (<year>2016</year>): <fpage>3</fpage>&#x02013;<lpage>15</lpage>, <pub-id pub-id-type="doi">10.3892/ijmm.2016.2620</pub-id>.<pub-id pub-id-type="pmid">27245147</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="tca70016-cit-0018">
<string-name>
<given-names>V.</given-names>
<surname>Subbiah</surname>
</string-name>, <string-name>
<given-names>N. O.</given-names>
<surname>Iannotti</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gutierrez</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>FIGHT&#x02010;101, a First&#x02010;In&#x02010;Human Study of Potent and Selective FGFR 1&#x02010;3 Inhibitor Pemigatinib in Pan&#x02010;Cancer Patients With FGF/FGFR Alterations and Advanced Malignancies</article-title>,&#x0201d; <source>Annals of Oncology</source>
<volume>33</volume> (<year>2022</year>): <fpage>522</fpage>&#x02013;<lpage>533</lpage>, <pub-id pub-id-type="doi">10.1016/j.annonc.2022.02.001</pub-id>.<pub-id pub-id-type="pmid">35176457</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="tca70016-cit-0019">
<string-name>
<given-names>A.</given-names>
<surname>Gupta</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Kurzrock</surname>
</string-name>, and <string-name>
<given-names>J. J.</given-names>
<surname>Adashek</surname>
</string-name>, &#x0201c;<article-title>Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the &#x02018;NSCLC&#x02019; of GI Oncology?</article-title>,&#x0201d; <source>Cancers</source>
<volume>15</volume>, no. <issue>5</issue> (<year>2023</year>): <elocation-id>1578</elocation-id>, <pub-id pub-id-type="doi">10.3390/cancers15051578</pub-id>.<pub-id pub-id-type="pmid">36900367</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="tca70016-cit-0020">
<string-name>
<given-names>V.</given-names>
<surname>S</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>N</surname>
</string-name>, <string-name>
<given-names>B. D.</given-names>
<surname>Kurmi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>An Expedition on Synthetic Methodology of FDA&#x02010;Approved Anticancer Drugs</article-title>,&#x0201d; <source>Anti&#x02010;Cancer Agents in Medicinal Chemistry</source>
<volume>24</volume>, no. <issue>8</issue> (<year>2024</year>): <fpage>590</fpage>&#x02013;<lpage>626</lpage>, <pub-id pub-id-type="doi">10.2174/0118715206259585240105051941</pub-id>.<pub-id pub-id-type="pmid">38288815</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="tca70016-cit-0021">
<string-name>
<given-names>P.</given-names>
<surname>Bansal</surname>
</string-name>, <string-name>
<given-names>D. K.</given-names>
<surname>Dwivedi</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Hatwal</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma</article-title>,&#x0201d; <source>Anti&#x02010;Cancer Agents in Medicinal Chemistry</source>
<volume>21</volume> (<year>2021</year>): <fpage>2478</fpage>&#x02013;<lpage>2486</lpage>, <pub-id pub-id-type="doi">10.2174/1871520621666210121093852</pub-id>.<pub-id pub-id-type="pmid">33475078</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="tca70016-cit-0022">
<string-name>
<given-names>S.</given-names>
<surname>Dai</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Chen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors</article-title>,&#x0201d; <source>Cells</source>
<volume>8</volume>, no. <issue>6</issue> (<year>2019</year>): <elocation-id>614</elocation-id>, <pub-id pub-id-type="doi">10.3390/cells8060614</pub-id>.<pub-id pub-id-type="pmid">31216761</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="tca70016-cit-0023">
<string-name>
<given-names>A.</given-names>
<surname>Markham</surname>
</string-name>, &#x0201c;<article-title>Erdafitinib: First Global Approval</article-title>,&#x0201d; <source>Drugs</source>
<volume>79</volume> (<year>2019</year>): <fpage>1017</fpage>&#x02013;<lpage>1021</lpage>, <pub-id pub-id-type="doi">10.1007/s40265-019-01142-9</pub-id>.<pub-id pub-id-type="pmid">31161538</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="tca70016-cit-0024">
<string-name>
<given-names>X.</given-names>
<surname>Meng</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Ji</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S&#x02010;Phase Cell&#x02010;Cycle Arrest as a CDK2 Inhibitor</article-title>,&#x0201d; <source>Molecules</source>
<volume>27</volume>, no. <issue>19</issue> (<year>2022</year>): <elocation-id>6733</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules27196733</pub-id>.<pub-id pub-id-type="pmid">36235266</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="tca70016-cit-0025">
<string-name>
<given-names>R.</given-names>
<surname>Roskoski</surname>, <suffix>Jr.</suffix>
</string-name>, &#x0201c;<article-title>Properties of FDA&#x02010;Approved Small Molecule Protein Kinase Inhibitors: A 2020 Update</article-title>,&#x0201d; <source>Pharmacological Research</source>
<volume>152</volume> (<year>2020</year>): <elocation-id>104609</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.phrs.2019.104609</pub-id>.<pub-id pub-id-type="pmid">31862477</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="tca70016-cit-0026">
<string-name>
<given-names>J. D.</given-names>
<surname>Karkera</surname>
</string-name>, <string-name>
<given-names>G. M.</given-names>
<surname>Cardona</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Bell</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib</article-title>,&#x0201d; <source>Molecular Cancer Therapeutics</source>
<volume>16</volume> (<year>2017</year>): <fpage>1717</fpage>&#x02013;<lpage>1726</lpage>, <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0518</pub-id>.<pub-id pub-id-type="pmid">28416604</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="tca70016-cit-0027">
<string-name>
<given-names>R.</given-names>
<surname>Roskoski</surname>, <suffix>Jr.</suffix>
</string-name>, &#x0201c;<article-title>Properties of FDA&#x02010;Approved Small Molecule Protein Kinase Inhibitors: A 2022 Update</article-title>,&#x0201d; <source>Pharmacological Research</source>
<volume>175</volume> (<year>2022</year>): <elocation-id>106037</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.phrs.2021.106037</pub-id>.<pub-id pub-id-type="pmid">34921994</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="tca70016-cit-0028">
<string-name>
<given-names>M</given-names>. <surname>Peng</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Deng</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>Li</surname>
</string-name>, &#x0201c;<article-title>Clinical Advances and Challenges in Targeting FGF/FGFR Signaling in Lung Cancer</article-title>,&#x0201d; <source>Molecular Cancer</source>
<volume>23</volume> (<year>2024</year>): <fpage>256</fpage>, <pub-id pub-id-type="doi">10.1186/s12943-024-02167-9.</pub-id>.<pub-id pub-id-type="pmid">39543657</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="tca70016-cit-0029">
<string-name>
<given-names>F. C.</given-names>
<surname>Detterbeck</surname>
</string-name>, <string-name>
<given-names>D. J.</given-names>
<surname>Boffa</surname>
</string-name>, <string-name>
<given-names>A. W</given-names>. <surname>Kim</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Eighth Edition Lung Cancer Stage Classification</article-title>,&#x0201d; <source>Chest</source>
<volume>151</volume> (<year>2017</year>): <fpage>193</fpage>&#x02013;<lpage>203</lpage>, <pub-id pub-id-type="doi">10.1016/j.chest.2016.10.010</pub-id>.<pub-id pub-id-type="pmid">27780786</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="tca70016-cit-0030">
<string-name>
<given-names>T.</given-names>
<surname>Helsten</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Elkin</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Arthur</surname>
</string-name>, <string-name>
<given-names>B. N.</given-names>
<surname>Tomson</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Carter</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Kurzrock</surname>
</string-name>, &#x0201c;<article-title>The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next&#x02010;Generation Sequencing</article-title>,&#x0201d; <source>Clinical Cancer Research</source>
<volume>22</volume> (<year>2016</year>): <fpage>259</fpage>&#x02013;<lpage>267</lpage>, <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-3212</pub-id>.<pub-id pub-id-type="pmid">26373574</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="tca70016-cit-0031">
<string-name>
<given-names>W.</given-names>
<surname>Zuo</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>He</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Li</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients</article-title>,&#x0201d; <source>Journal of Cancer</source>
<volume>11</volume> (<year>2020</year>): <fpage>6695</fpage>&#x02013;<lpage>6699</lpage>, <pub-id pub-id-type="doi">10.7150/jca.49269</pub-id>.<pub-id pub-id-type="pmid">33046990</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="tca70016-cit-0032">
<string-name>
<given-names>L. P.</given-names>
<surname>Andrews</surname>
</string-name>, <string-name>
<given-names>A. R.</given-names>
<surname>Cillo</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Karapetyan</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Kirkwood</surname>
</string-name>, <string-name>
<given-names>C. J.</given-names>
<surname>Workman</surname>
</string-name>, and <string-name>
<given-names>D. A. A.</given-names>
<surname>Vignali</surname>
</string-name>, &#x0201c;<article-title>Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy</article-title>,&#x0201d; <source>Clinical Cancer Research</source>
<volume>28</volume> (<year>2022</year>): <fpage>5030</fpage>&#x02013;<lpage>5039</lpage>, <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-2390</pub-id>.<pub-id pub-id-type="pmid">35579997</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="tca70016-cit-0033">
<string-name>
<given-names>A. O.</given-names>
<surname>Kamphorst</surname>
</string-name>, <string-name>
<given-names>R. N.</given-names>
<surname>Pillai</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Yang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Proliferation of PD&#x02010;1+ CD8 T Cells in Peripheral Blood After PD&#x02010;1&#x02010;Targeted Therapy in Lung Cancer Patients</article-title>,&#x0201d; <source>Proceedings of the National Academy of Sciences of the United States of America</source>
<volume>114</volume> (<year>2017</year>): <fpage>4993</fpage>&#x02013;<lpage>4998</lpage>, <pub-id pub-id-type="doi">10.1073/pnas.1705327114</pub-id>.<pub-id pub-id-type="pmid">28446615</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="tca70016-cit-0034">
<string-name>
<given-names>B.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Feng</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Temporal Single&#x02010;Cell Tracing Reveals Clonal Revival and Expansion of Precursor Exhausted T Cells During Anti&#x02010;PD&#x02010;1 Therapy in Lung Cancer</article-title>,&#x0201d; <source>Nature Cancer</source>
<volume>3</volume> (<year>2022</year>): <fpage>108</fpage>&#x02013;<lpage>121</lpage>, <pub-id pub-id-type="doi">10.1038/s43018-021-00292-8</pub-id>.<pub-id pub-id-type="pmid">35121991</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="tca70016-cit-0035">
<string-name>
<given-names>D. S.</given-names>
<surname>Thommen</surname>
</string-name>, <string-name>
<given-names>V. H.</given-names>
<surname>Koelzer</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Herzig</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Transcriptionally and Functionally Distinct PD&#x02010;1(+) CD8(+) T Cell Pool With Predictive Potential in Non&#x02010;Small&#x02010;Cell Lung Cancer Treated With PD&#x02010;1 Blockade</article-title>,&#x0201d; <source>Nature Medicine</source>
<volume>24</volume> (<year>2018</year>): <fpage>994</fpage>&#x02013;<lpage>1004</lpage>, <pub-id pub-id-type="doi">10.1038/s41591-018-0057-z</pub-id>.</mixed-citation></ref><ref id="tca70016-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="tca70016-cit-0036">
<string-name>
<given-names>S.</given-names>
<surname>Corgnac</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Boutet</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kfoury</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Naltet</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Mami&#x02010;Chouaib</surname>
</string-name>, &#x0201c;<article-title>The Emerging Role of CD8(+) Tissue Resident Memory T (T(RM)) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>9</volume> (<year>2018</year>): <elocation-id>1904</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2018.01904</pub-id>.<pub-id pub-id-type="pmid">30158938</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="tca70016-cit-0037">
<string-name>
<given-names>S.</given-names>
<surname>Corgnac</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Malenica</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Mezquita</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>CD103(+)CD8(+) T(RM) Cells Accumulate in Tumors of Anti&#x02010;PD&#x02010;1&#x02010;Responder Lung Cancer Patients and Are Tumor&#x02010;Reactive Lymphocytes Enriched With Tc17</article-title>,&#x0201d; <source>Cell Reports Medicine</source>
<volume>1</volume> (<year>2020</year>): <elocation-id>100127</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100127</pub-id>.<pub-id pub-id-type="pmid">33205076</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="tca70016-cit-0038">
<string-name>
<given-names>G. W.</given-names>
<surname>Stratton</surname>
</string-name> and <string-name>
<given-names>T. M.</given-names>
<surname>Smith</surname>
</string-name>, &#x0201c;<article-title>Interaction of Organic Solvents With the Green Alga <italic toggle="yes">Chlorella pyrenoidosa</italic>
</article-title>,&#x0201d; <source>Bulletin of Environmental Contamination and Toxicology</source>
<volume>40</volume> (<year>1988</year>): <fpage>736</fpage>&#x02013;<lpage>742</lpage>, <pub-id pub-id-type="doi">10.1007/BF01697524</pub-id>.<pub-id pub-id-type="pmid">3382790</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="tca70016-cit-0039">
<string-name>
<given-names>G. Z.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>X. C.</given-names>
<surname>Zhao</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Aryl Hydrocarbon Receptor Mediates Tobacco&#x02010;Induced PD&#x02010;L1 Expression and Is Associated With Response to Immunotherapy</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>10</volume> (<year>2019</year>): <elocation-id>1125</elocation-id>, <pub-id pub-id-type="doi">10.1038/s41467-019-08887-7</pub-id>.</mixed-citation></ref><ref id="tca70016-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="tca70016-cit-0040">
<string-name>
<given-names>X.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Ricciuti</surname>
</string-name>, <string-name>
<given-names>J. V.</given-names>
<surname>Alessi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non&#x02010;Small Cell Lung Cancer</article-title>,&#x0201d; <source>Journal of the National Cancer Institute</source>
<volume>113</volume> (<year>2021</year>): <fpage>1761</fpage>&#x02013;<lpage>1769</lpage>, <pub-id pub-id-type="doi">10.1093/jnci/djab116</pub-id>.<pub-id pub-id-type="pmid">34115098</pub-id>
</mixed-citation></ref><ref id="tca70016-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="tca70016-cit-0041">
<string-name>
<given-names>E. S.</given-names>
<surname>Knudsen</surname>
</string-name>, <string-name>
<given-names>S. C.</given-names>
<surname>Pruitt</surname>
</string-name>, <string-name>
<given-names>P. A.</given-names>
<surname>Hershberger</surname>
</string-name>, <string-name>
<given-names>A. K.</given-names>
<surname>Witkiewicz</surname>
</string-name>, and <string-name>
<given-names>D. W.</given-names>
<surname>Goodrich</surname>
</string-name>, &#x0201c;<article-title>Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy</article-title>,&#x0201d; <source>Trends Cancer</source>
<volume>5</volume> (<year>2019</year>): <fpage>308</fpage>&#x02013;<lpage>324</lpage>, <pub-id pub-id-type="doi">10.1016/j.trecan.2019.03.005</pub-id>.<pub-id pub-id-type="pmid">31174843</pub-id>
</mixed-citation></ref></ref-list></back></article>